COMBINATION FOR THE TREATMENT OF INFECTIONS CAUSED BY MYCOPLASMA GENITALIUM
The present invention relates to methods for treating bacterial infections caused by or associated with Mycoplasma genitalium , which comprises administration of gepotidacin or pharmaceutically acceptable salts thereof, and doxycycline to a human in need thereof. Novel pharmaceutical combinations, compositions, resistance guided therapies and/or corresponding uses thereof are also disclosed.
1 . A method for treating an infection caused by Mycoplasma genitalium in a human in need thereof, comprising administering to said human a therapeutically effective amount of gepotidacin or a pharmaceutically acceptable salt thereof, with a therapeutically effective amount of doxycycline.
2 . A method as claimed in claim 1 , wherein the infection is selected from: sexually transmitted infections or diseases, bacterial causes of female infertility, genital tract infections and co-infection associated urinary tract infections.
3 . A method as claimed in claim 1 , wherein the infection is urethritis.
4 . A method as claimed in claim 3 , wherein the infection is non-gonococcal urethritis.
5 . A method as claimed in claim 1 wherein the Mycoplasma genitalium causing the infection is resistant to azithromycin or moxifloxacin.
6 . A method as claimed in claim 1 wherein the gepotidacin or a pharmaceutically acceptable salt thereof, and doxycycline, are administered sequentially.
7 . A method as claimed in claim 1 , wherein the gepotidacin is administered in the form of gepotidacin methanesulphonate.
8 . A method as claimed in claim 1 , wherein the gepotidacin or a pharmaceutically acceptable salt thereof is administered orally.
9 . A method as claimed in claim 1 , wherein the doxycycline is administered orally.
10 - 15 . (canceled)
16 . A pharmaceutical combination which comprises gepotidacin or a pharmaceutically acceptable salt thereof and doxycycline.
17 . A pharmaceutical composition which comprises gepotidacin or a pharmaceutically acceptable salt thereof, doxycycline, and at least one pharmaceutically acceptable excipient(s).
18 - 20 . (canceled)